Trial Search Results
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver
The primary aim of this trial is to comparing three techniques of liver embolization:
1. “Bland” embolization, in which tiny plastic beads are injected into the artery to the liver to cut off blood flow to the tumors;
2. Conventional “TACE” (transarterial chemoembolization), injecting an oily emulsion (mixture) of chemotherapy (doxorubicin) with the plastic beads; and
3. “DEB” TACE (drug-eluting bead chemoembolization), in which a chemotherapy drug (doxorubicin) is directly loaded (absorbed) on the plastic beads which are used for the injection
All three of these techniques are equally used in practice in the United States and all have similarly good immediate results controlling tumors in the liver.
Stanford is currently not accepting patients for this trial.
Abramson Cancer Center of the University of Pennsylvania
- Device: Bland Embolization
- Combination Product: Transarterial chemoembolization
- Combination Product: Drug Eluting Beads Embolization
- Participants 18 years and older;
- Biopsy-proven neuroendocrine tumor.
- Measurable metastasis to liver with at least one dimension ≥ 1.0 cm.
- Tumor burden dominant in the liver AND liver tumor burden less than or equal to 70% of
the total liver volume by visual estimate.
- Not a candidate for surgical resection based on unresectability, anatomy, anesthesia
risk, patient preference.
- Symptoms uncontrolled by somatostatin analogues OR morphologically progressive tumor
by RECIST 1.1 criteria in the liver OR baseline tumor burden >25% of the liver volume.
- There must be no plans for the patient to receive other concomitant therapy while on
this protocol treatment (other than somatostatin analogs or bone-strengthening
- Performance status 0-2 on Zubrod/ECOG Performance Scale;
- Serum creatinine < 2.0 mg/dL;
- Serum Bilirubin ≤ 2.0 mg/dL
- Serum albumin ≥ 3.0 g/dL
- Platelet count > 50 thousands/uL (corrected if needed)
- INR ≤ 1.5 (corrected if needed)
- All patients must be informed of the investigational nature of this study and must
sign a study specific informed consent in accordance with institutional and federal
guidelines prior to study entry.
- Pregnant or lactating women may not participate due to the embryotoxic effects of
protocol treatment. Women/men of reproductive potential may not participate unless
they have agreed to use an effective contraceptive method.
- Prior hepatic arterial therapy or hepatic radiation therapy. Prior surgical resection
or ablation of liver metastases is acceptable. Patients must be at least one month
beyond prior chemotherapy, PRRT, ablation or surgery, and have recovered from all
- Active infection (Symptomatic bacterial and fungal infection - newly diagnosed and/or
- Choledochoenteric anastomosis; transpapillary biliary stent, or sphincterotomy of
- Absolute contraindication to intravenous iodinated contrast (Hx of significant
previous contrast reaction, not mitigated by appropriate pre-medication).
- Contraindications to arteriography and selective visceral catheterization:
1. severe allergy or intolerance to contrast media, narcotics, sedatives, or
2. bleeding diathesis not correctable by usual forms of therapy.
3. severe peripheral vascular disease precluding catheterization.
- Contraindications to hepatic artery embolization:
1. portal vein occlusion without hepatopedal collateral flow demonstrated by
angiography; or portal hypertension with hepatofugal flow.
2. hepatic encephalopathy.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study